Evaluation of Depression and Anxiety Disorders and Correlation with the Treatment of Patients with Psoriasis Vulgaris

Keywords: Anxiety, Anxiety Disorders, Depression, Depressive Disorder, Psoriasis/complications, Psoriasis/psychology


Introduction: Psoriasis is a chronic inflammatory multisystemic disease with several comorbidities, namely anxiety and depression disorders.

Methods: In this study, the prevalence of these psychiatric entities was investigated by the PHQ-9 and GAD-7 questionnaries and related to the socio-demographic variables and to the forms of clinical treatment.

Results: A total of 90 patients (56 females) were analyzed. Of these, 41 patients (45.56%) used topical treatment only, 28 patients (31.11%) used oral methotrexate and 21 patients (23.33%) used immunobiological agents (anti-TNF-alfa agents). It was observed that 47 patients (52.23%) presented some degree of depression (mild, moderate or severe) and 53 patients (58.89%) presented some degree of anxiety disorder (mild, moderate or severe). There was no statistical relationship between the anxiety and depression scores and the PASI score, as well as age, employability or schooling. There was a statistical association between psychiatric comorbidities and the female gender (p <0.0001). It was also observed a lower prevalence of depression (p = 0.0336) on patients using immunobiological treatments.

Conclusion: The findings confirm published data, showing association of psychiatric conditions with psoriasis, especially in relation to TNF-alpha, so that anti-TNF therapies may become an alternative for the treatment of depression or anxiety disorders associated with psoriasis.


Download data is not yet available.


Azulay RD, Azulay DR. Dermatologia. 6th ed. Rio de Janeiro: Ganabara Koogan; 2015.

Nestle FO, Kaplan DH, Barker J. Mechanisms of Disease: Psoriasis. New Engl J Med. 2009; 361:496-509.

Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995; 32:982-6.

Kothiwala SK, Khanna N, Tandon N, Naik N, Sharma VK, Sharma S, et al. Prevalence of metabolic syndrome and cardiovascular changes in patients with chronic plaque psoriasis and their correlation with disease severity: A hospital-based cross-sectional study. Indian J Dermatol Venereol Leprol. 2016;82:510-8. doi: 10.4103/0378-6323.183638.

Gerdes S, Mrowietz U, Boehncke WH. Comorbidity in psoriasis. Hautarzt. 2016; 67:438-44.

Rapp SR, Feldman SR, Exum ML, Fleischer Jr AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41:401-7.

Egeberg A, Khalid U, Gislason GH, Mallbris L, Skov L, Hansen PR. Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study. Br J Dermatol. 2015; 173:471-9. doi: 10.1111/bjd.13778.

Lamb RC, Matcham F, Turner MA, Rayner L, Simpson A, Hotopf M, et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol. 2017; 176:1028-34. doi: 10.1111/bjd.14833.

Kouris A, Christodoulou C, Efstathiou V, Tsatovidou R, Torlidi-Kordera E, Zouridaki E, et al. Comparative study of quality of life and psychosocial characteristics in patients with psoriasis and leg ulcers. Wound Repair Regen. 2016; 24:443-6.

Molina-Leyva A, Molina-Leyva I, Almodovar-Real A, Ruiz-Carrascosa JC, Naranjo-Sintes R, Jimenez-Moleon JJ. Prevalence and associated factors of erectile dysfunction in patients with moderate to severe psoriasis and healthy population: a comparative study considering physical and psychological factors. Arch Sex Behav. 2016; 45:2047-55.

Tohid H, Aleem D, Jackson C. Major depression and psoriasis: A Psychodermatological phenomenon. Skin Pharmacol Psysiol. 2016; 29: 220-30.

Kannan S, Heller MM, Lee ES, Koo JY. The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should know. J Dermatol Treat. 2013; 24:148-152. doi: 10.3109/09546634.2011.619159.

Khawaja AR, Bokhari SMA, Rasheed T, Shahzad A, Hanif M, Qadeer F, et al. Disease severity, quality of life, and psychiatric morbidity in patients with psoriasis with reference to sociodemographic, lifestyle, and clinical variables: a prospective, cross-sectional study from Lahore, Pakistan. Prim Care Companion CNS Disord. 2015;17:10.4088/PCC.14m01629. doi: 10.4088/PCC.14m01629.

Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16:606-13.

Kroenke K, Spitzer RL, Williams JB, Löwe B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010; 32:345-59. doi: 10.1016/j.genhosppsych.2010.03.006.

Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006166:1092-7. doi: 10.1001/archinte.166.10.1092.

DiBonaventura M, Carvalho AVE, Souza CS, Squiassi HB, Ferreira CN. Associação entre psoríase e qualidade de vida relacionada a saúde, produtividade no trabalho e uso de recursos de saúde no Brasil. An Brasil Dermatol. 2018; 93:198-206.

Hrehorów E, Salomon J, Matusiak U, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012; 92:67-72.

Adisen E, Uzun S, Erduran F, Ali Gurer M. Prevalência de tabagismo, consumo de álcool e síndrome metabólica em pacientes com psoríase. An Bras Dermatol. 2018; 93:207-13.

Roque Ferreira B, Pio-Abreu JL, Reis JP, Figueiredo A. Analysis of the prevalence of mental disorders in psoriasis: the relevance of psychiatric assessment in dermatology. Psychiatria Danubina. 2017; 29:401-6.

Strober B, Gooderham M, de Jong EM, Kimball AB, Langley RG, Lakdawala N, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2018; 78:70-80. doi: 10.1016/j.jaad.2017.08.051.

Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytocine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018; 23:335-43.

Shariq AS, Brietzke E, Rosenblat JD, Barendra V, Pan Z, McIntyre RS. Targeting cytokines in reduction of depressive symptoms: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 83:86-91. doi: 10.1016/j.pnpbp.2018.01.003.

Patel N, Nadkarni A, Cardwell LA, Vera N, Frey C, Patel N, et al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol . 2017; 18:613-20. doi: 10.1007/s40257-017-0279-8.

Zhou R, Wang F, Zhao G, Xia W, Peng D, Mao R, et al. Effects of tumor necrosis factor-α polymorphism on the brain structural changes of the patients with major depressive disorder. Transl Psychiatry. 2018;8:217. doi: 10.1038/s41398-018-0256-x.

Azambuja RD. A necessidade de cuidado conjunto de dermatologistas, psiquiatras e psicólogos em Psicodermatologia. An Brasil Dermatol. 2017; 92:60-8

How to Cite
Kamilly Leitão Pitman Machado, A., Vinicius Botelho Brito, C., Augusto Gomes de Souza Monteiro de Brito, J., Andrea Avelar Pires, C., & Regina Oliveira Carneiro, F. (2020). Evaluation of Depression and Anxiety Disorders and Correlation with the Treatment of Patients with Psoriasis Vulgaris. Journal of the Portuguese Society of Dermatology and Venereology, 78(4), 321-327. https://doi.org/10.29021/spdv.78.4.1224
Original Articles